Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Earnings for Intercept Pharmaceuticals, Inc. (ICPT)
Earnings in 2022 (TTM): $-174,858,000
According to Intercept Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-174,858,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Intercept Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-174,858,000 | $115.17 M |
| 2021 | $-91,426,000 | $-145,022,000 |
| 2020 | $-274,880,000 | $-324,230,000 |
| 2019 | $-344,681,000 | $-391,052,000 |
| 2018 | $-309,242,000 | $-309,242,000 |
| 2017 | $-360,367,000 | $-360,367,000 |
| 2016 | $-412,830,000 | $-412,830,000 |
| 2015 | $-226,429,000 | $-226,429,000 |
| 2014 | $-283,226,000 | $-283,226,000 |
| 2013 | $-67,792,410 | $-67,792,410 |
| 2012 | $-43,644,000 | $-43,644,000 |
| 2011 | $-13,830,454 | $-12,737,654 |
| 2010 | $-15,087,223 | $-15,087,223 |